Your browser doesn't support javascript.
loading
LSD1-directed therapy affects glioblastoma tumorigenicity by deregulating the protective ATF4-dependent integrated stress response.
Faletti, Stefania; Osti, Daniela; Ceccacci, Elena; Richichi, Cristina; Costanza, Brunella; Nicosia, Luciano; Noberini, Roberta; Marotta, Giulia; Furia, Laura; Faretta, Mario R; Brambillasca, Silvia; Quarto, Micaela; Bertero, Luca; Boldorini, Renzo; Pollo, Bianca; Gandini, Sara; Cora, Davide; Minucci, Saverio; Mercurio, Ciro; Varasi, Mario; Bonaldi, Tiziana; Pelicci, Giuliana.
  • Faletti S; Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan 20139, Italy.
  • Osti D; Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan 20139, Italy.
  • Ceccacci E; Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan 20139, Italy.
  • Richichi C; Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan 20139, Italy.
  • Costanza B; Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan 20139, Italy.
  • Nicosia L; Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan 20139, Italy.
  • Noberini R; Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan 20139, Italy.
  • Marotta G; Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan 20139, Italy.
  • Furia L; Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan 20139, Italy.
  • Faretta MR; Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan 20139, Italy.
  • Brambillasca S; Experimental Therapeutics Program, FIRC Institute of Molecular Oncology Foundation (IFOM), Milan 20139, Italy.
  • Quarto M; Experimental Therapeutics Program, FIRC Institute of Molecular Oncology Foundation (IFOM), Milan 20139, Italy.
  • Bertero L; Department of Medical Sciences, University of Turin, Turin 10126, Italy.
  • Boldorini R; Department of Health Science, University of Piemonte Orientale (UPO), Novara 28100, Italy.
  • Pollo B; Unit of Neuropathology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan 20133, Italy.
  • Gandini S; Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan 20139, Italy.
  • Cora D; Department of Translational Medicine, Center for Translational Research on Autoimmune and Allergic Disease (CAAD), University of Piemonte Orientale, Novara 28100, Italy.
  • Minucci S; Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan 20139, Italy.
  • Mercurio C; Experimental Therapeutics Program, FIRC Institute of Molecular Oncology Foundation (IFOM), Milan 20139, Italy.
  • Varasi M; Experimental Therapeutics Program, FIRC Institute of Molecular Oncology Foundation (IFOM), Milan 20139, Italy.
  • Bonaldi T; Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan 20139, Italy.
  • Pelicci G; Department of Experimental Oncology, European Institute of Oncology (IEO), IRCCS, Milan 20139, Italy.
Sci Transl Med ; 13(623): eabf7036, 2021 12 08.
Article en En | MEDLINE | ID: mdl-34878824
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Glioblastoma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Encefálicas / Glioblastoma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Año: 2021 Tipo del documento: Article